Cancer

August 3, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced ovarian cancer and other metastatic cancers: A pharmaceutical mixture encompassing Olaparib, an FDA-approved poly (adenosine diphosphate-ribose) polymerase inhibitor, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as FASLG, KLF5,  p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 4/August/2019, 1.11 am

Introduction: What they say: A study from the Stephenson Cancer Center at the University of Oklahoma, Oklahoma City (K.M.), USA; University of Milan-Bicocca, European Institute of […]
August 2, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in chronic lymphocytic leukemia (CLL) and in advanced metastatic cancers: A pharmaceutical mixture encompassing Venetoclax and Ibrutinib (VAI) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as LZTFL1 (Leucine Zipper Transcription Factor Like 1), ACAT1 (Acetyl-CoA Acetyltransferase 1), p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls CLL progression, via up-regulation of its target gene, 02/August/2019, 11.13 pm

Introduction: What they say A study from the University of Texas M.D. Anderson Cancer Center, Houston, USA shows that “Ibrutinib and Venetoclax for First-Line Treatment of CLL.” This research […]
July 4, 2019

Probiotic-based therapy for aging-associated diseases and Lifespan extension: Probiotic Lactobacillus Fermentum DR9 ( (LF-DR9)  inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and aging, via down-regulation of its target gene, 4/July/2019, 8.17 am

Introduction: What they say A study from Department of Genetics, Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA, USA; and […]
June 20, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in chronic lymphocytic leukemia (CLL) and in advanced metastatic cancers: A pharmaceutical mixture encompassing Venetoclax and Ibrutinib (VAI) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as HNF4α, PP2A, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, and stalls CLL progression, via up-regulation of its target gene, 20/June/2019, 7.33 am

Introduction: What they say A study from the University of Texas M.D. Anderson Cancer Center, Houston, USA shows that “Ibrutinib and Venetoclax for First-Line Treatment of CLL.” This research […]